FY2026 Earnings Estimate for LLY Issued By Cantor Fitzgerald

Eli Lilly and Company (NYSE:LLY - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Eli Lilly and Company in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Gould forecasts that the company will earn $32.40 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $975.00 target price on the stock. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share.

LLY has been the topic of several other research reports. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. UBS Group cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, June 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Stock Up 0.8%

Eli Lilly and Company stock traded up $6.53 during midday trading on Tuesday, hitting $818.56. 2,753,537 shares of the stock were exchanged, compared to its average volume of 3,651,762. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The stock has a market capitalization of $775.78 billion, a price-to-earnings ratio of 69.90, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41. The business's 50-day moving average price is $775.43 and its 200-day moving average price is $801.50. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.58 earnings per share.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.73%. Eli Lilly and Company's payout ratio is 48.82%.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors have recently made changes to their positions in the stock. WestEnd Advisors LLC grew its holdings in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $27,000. Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $40,000. Finally, Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $43,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.